Press Release August 20, 2021

Capital Markets Team Advises Underwriters of $144.6 Million Omega Therapeutics IPO

The Life Sciences IPOs & Capital Markets team advised Goldman Sachs & Co. LLC and the other underwriters of Omega Therapeutics, Inc.’s (Nasdaq: OMGA) initial public offering of 8,5100,000 shares of its common stock at a price to the public of $17 per share, including full exercise of the underwriter’s option to purchase additional shares. The gross proceeds from the offering, before deducting underwriting discounts and commissions and estimated offering expenses payable by Omega, are expected to be approximately $144.6 million.

Omega is a development-stage biotechnology company leveraging its OMEGA Epigenomic Programming™ platform to harness the power of epigenetics to develop a new class of DNA-sequence-targeting, mRNA-encoded programmable epigenetic medicines.

The Goodwin team was led by Stuart Cable, Robert Puopolo, Seo Salimi, Will Magioncalda, Marishka DeToy, Amanda Rae Schwarzenbart, Dan Liu, and Jahid Mowla (Corporate); and included Duncan Greenhalgh and Lily Xu (Intellectual Property); Julie Tibbets, Elizabeth Mulkey, and Seth Gitner (FDA); and Roger Cohen, Anne Brendel, and Andrew Hess (Healthcare).

For more details, read the press release and articles in Boston Business Journal, Seeking Alpha, and Market Watch.